Rifabutin (Ansamycin)

Subscribe to Selected New Research on Rifabutin

420 relevant articles (53 outcomes, 66 trials/studies) found for this Drug

Description: A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.

Also Known As:

Ansamycin; Mycobutin; Alfacid; Ansatipin; Ansatipine; Grünenthal Brand of Rifabutin; Kenfarma Brand of Rifabutin; LM-427; Pharmacia Brand of Rifabutin; Rifabutine; LM 427; LM427; Rifamycin XIV, 1',4-didehydro-1-deoxy-1,4-dihydro-5'-(2-methylpropyl)-1-oxo-

Relationship Network

Drug Context: Research Results

Experts

1.	Peloquin, Charles A: 5 articles (08/2008 - 08/2003)
2.	Tuberculosis Trials Consortium: 3 articles (06/2007 - 05/2005)
3.	Gaspar, M M: 2 articles (01/2008 - 09/2000)
4.	Pedrosa, J: 2 articles (01/2008 - 09/2000)
5.	Silva-Trigo, Claudia: 2 articles (06/2007 - 05/2005)
6.	Engle, Melissa: 2 articles (06/2007 - 11/2005)
7.	Zhao, Zhen: 2 articles (11/2005 - 05/2005)
8.	Vernon, Andrew: 2 articles (11/2005 - 05/2005)
9.	Burman, William: 2 articles (11/2005 - 05/2005)
10.	Benator, Debra: 2 articles (11/2005 - 05/2005)

Related Diseases

1.	Infection 11/01/1994 - "KRM showing much more potent in vitro activity against the MAC organisms compared to rifabutin (RBT) and RFP, also exerted markedly greater therapeutic efficacy against the MAC infections induced in mice or rabbits in terms of reducing the incidence and the extent of gross pulmonary lesions and the bacterial loads in the lungs and spleens. " 04/01/1994 - "Clinical tests on more than 1,000 patients have shown the benefit of Ansatipine in the prophylactic treatment of MAC infections: reduction by half on the frequency of surveillance, prolongation of the delay in appearance, significant improvement in general condition and quality of life of the patients. " 11/01/1988 - "Rifabutin was moderately effective against an environmental serotype 8 strain of MAC and of significant effectiveness against low dose aerogenic infections with two strains of higher virulence. " 01/01/2007 - "BACKGROUND: Rifabutin has been found to be effective in multi-resistant patients after various treatment cycles for Helicobacter pylori (HP) infection, but it has not been analysed as a second-line treatment. " 09/01/2000 - "Therapeutic efficacy of liposomal rifabutin in a Mycobacterium avium model of infection." Order ALL the reference details at left...
2.	Acquired Immunodeficiency Syndrome (AIDS) 12/01/1995 - "CONCLUSIONS: An analysis of the combined double-blind and open-label follow-up of two clinical trials of rifabutin prophylaxis for MAC supports the suggestion of the double-blind study that rifabutin improves survival of AIDS patients." 12/01/1995 - "METHODS: Data from 1146 AIDS patients with CD4+ counts < or = 200 x 10(6)/l enrolled at 73 US and Canadian sites in two clinical trials of MAC prophylaxis were analyzed using Cox proportional hazards analysis with rifabutin use modeled as a time-dependent covariate, taking into account the initial randomized double-blind phase of the trials and the subsequent open-label phase of follow-up of those patients. " 12/01/1995 - "Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS." 01/01/1995 - "Clinical trials have proven the therapeutic value of rifabutin especially in AIDS patients with concomitant MAC. " 05/01/2009 - "Rifabutin corneal deposits in a patient with acquired immunodeficiency syndrome: in vivo confocal microscopy investigation." Order ALL the reference details at left...
3.	Bacteremia 04/01/1994 - "Rifabutin reduced the incidence of MAC bacteremia by approximately one-half and, when disseminated disease due to MAC (DMAC) did develop, reduced the frequency of associated clinical symptoms. " 08/01/1999 - "The study included two patient groups: 73 HIV-infected patients with CD4 counts of < 100 cells/microL (mean 30 cells/microL) who were treated between February 1992 and July 1993 and who had not received rifabutin prophylaxis (Group R-), as well as 90 HIV-infected patients with CD4 counts of < 100 cells/microL (mean 22 cells/microL) who had received rifabutin 300 mg/day as primary prophylaxis against MAC bacteremia between July 1993 and November 1995 (Group R+). " 12/01/1995 - "OBJECTIVES: Rifabutin prophylaxis has been shown to significantly decrease the incidence of Mycobacterium avium complex (MAC) bacteremia in two randomized controlled clinical trials, but a survival benefit has not been observed. " 08/01/1995 - "Two randomized, placebo-controlled trials have demonstrated that prophylactic use of rifabutin in persons with low CD4 lymphocyte counts results in a 50% decrease in MAC bacteremia as well as a reduction in some signs, symptoms, and laboratory abnormalities associated with MAC disease. " 04/01/1994 - "Controlled trials of rifabutin for the prophylaxis of MAC bacteremia have been completed. " Order ALL the reference details at left...
4.	Crohn Disease (Crohn's Disease) 01/01/2002 - "Only 5 Crohn's disease patients (13.8%) were non-responders, noticing no marked improvement while on rifabutin and macrolide antibiotic therapy. " 01/01/2007 - "However, use of rifabutin in the management of Crohn's disease is controversial and not widely known to an ophthalmic readership. " 02/01/2006 - "Corneal endothelial deposits associated with rifabutin treatment in Crohn's disease." 01/01/2002 - "CONCLUSION: The data add further evidence to support the role of rifabutin and macrolide antibiotic therapy in the treatment of Crohn's disease specifically in those patients with evidence of Mycobacterium avium subsp. " 01/01/2002 - "Three Crohn's disease patients [8. 3%) noticed significant improvements, but required other Crohn's medications, concurrently with rifabutin and macrolide antibiotic therapy, to achieve and sustain improvement. " Order ALL the reference details at left...
5.	HIV Infections (HIV Infection) 05/01/2009 - "PURPOSE: To establish the real localization of rifabutin-related corneal deposits in a patient with human immunodeficiency virus (HIV) infection by in vivo HRT II confocal microscopy with related clinicopathologic implications. " 02/01/1999 - "PURPOSE: To assess the potential ocular effects of prophylactic administration of rifabutin in children with symptomatic human immunodeficiency virus (HIV) infection and CD4 counts less than 50 cells per mm3. " 05/01/2001 - "Rifabutin is effective in the treatment and prevention of Mycobacterium avium infection in people with HIV infection. " 05/01/2009 - "After Siena University Institutional Review Board approval in May 2008 and specific informed consent, a 54-year-old patient with HIV infection under rifabutin treatment for acquired immunodeficiency syndrome-related Mycobacterium avium complex prevention who developed diffuse corneal deposits was examined at the Department of Ophthalmology of Siena University. " 06/01/1999 - "INTERPRETATION: Corneal endothelial deposits found in patients with HIV infection are associated with rifabutin use independent of the presence of CMV retinitis. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Clarithromycin (Biaxin)
2.	Ethambutol (Myambutol)
3.	Azithromycin (Zithromax)
4.	Clofazimine (Lamprene)
5.	Rifampin (Rifampicin)
6.	Atovaquone (Mepron)
7.	Isoniazid (Ftivazide)
8.	Macrolides
9.	Amikacin (A.M.K)
10.	Anti-Bacterial Agents (Antibiotics)

Related Therapies and Procedures

1.	Retreatment
2.	Blood Transfusion (Blood Transfusions)
3.	Drug Therapy (Chemotherapy)
4.	Heterologous Transplantation (Xenotransplantation)
5.	Highly Active Antiretroviral Therapy (HAART)

Best Treatments:
Research Summary Report
on Infection

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 14726 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>